Avidity Partners Management LP 13F: Quarter-over-Quarter Portfolio Changes
Avidity Partners Management LP reported a disclosed portfolio value of approximately $441.9 million in its latest SEC Form 13F-HR filing for Q1 2026, up 27.5% quarter on quarter. Over the quarter, the fund initiated 25 new positions, bought more shares in 9 holdings, trimmed 9 holdings, and exited 18 positions.
Avidity Partners Management LP's top buy was a new stake in Aktis Oncology INC (AKTS) , equal to 2.0% of the disclosed portfolio. Its top sell was Cg Oncology INC (CGON) . The fund exited the position completely after it had accounted for 17.6% of the previous portfolio.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| PALVELLA THERAPEUTICS INC NE | PVLA | +1.5% | +262.7% | History → |
| KARYOPHARM THERAPEUTICS INC | KPTI | +0.6% | +244.6% | Holders → |
| ENLIVEN THERAPEUTICS INC | ELVN | +3.1% | +185.1% | History → |
| PERSPECTIVE THERAPEUTICS | CATX | +2.8% | +88.4% | History → |
| REPLIGEN CORP | RGEN | +-0.3% | +54.7% | History → |
| CORCEPT THERAPEUTICS INC | CORT | +0.1% | +36.4% | Holders → |
| ENCOMPASS HEALTH CORP | EHC | +-0.0% | +32.9% | Holders → |
| PHATHOM PHARMACEUTICALS INC | PHAT | +-0.4% | +21.0% | Holders → |
| ORUKA THERAPEUTICS INC | ORKA | +6.0% | +15.1% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC. | ACAD | -0.8% | 87.9% | Holders → |
| IMMUNIC INC | IMUX | 0.7% | 85.7% | Holders → |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | -2.2% | 52.1% | Holders → |
| ICON PLC (ICLR) | ICLR | -1.3% | 51.7% | Holders → |
| BOSTON SCIENTIFIC CORP | BSX | -2.4% | 47.6% | Holders → |
| GENMAB A/S | GMAB | -0.5% | 45.7% | Holders → |
| NATERA | NTRA | -0.4% | 23.7% | Holders → |
| CONTEXT THERAPEUTICS INC | CNTX | 0.3% | 9.2% | History → |
| MEDTRONIC PLC | MDT | -1.1% | 7.1% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CG ONCOLOGY INC | CGON | 17.6% |
| ALNYLAM PHARMACEUTICALS, INC. | ALNY | 2.4% |
| MCKESSON CORP | MCK | 2.3% |
| AGILENT TECHNOLOGIES INC | A | 1.6% |
| PFIZER | PFE | 1.5% |
| CENTENE CORP DEL | CNC | 1.4% |
| KENVUE INC | KVUE | 1.2% |
| DANAHER | DHR | 1.1% |
| THERMO FISHER SCIENTIFIC INC | TMO | 1.1% |
| NOVO-NORDISK A S | NVO | 1.0% |
| THE CIGNA GROUP | CI | 0.9% |
| CENCORA INC | COR | 0.9% |
| INSMED INC | INSM | 0.9% |
| WATERS CORP | WAT | 0.9% |
| ACADIA HEALTHCARE COMPANY IN | ACHC | 0.7% |
| INTEGER HLDGS CORP | ITGR | 0.7% |
| HEALTHEQUITY INC | HQY | 0.4% |
| IQVIA HLDGS INC (IQV) | IQV | 0.3% |
Net Portfolio Value ChangeQ1 2026
- $0.3BPrior quarter
- $0.4BCurrent quarter
- +$0.1BNet delta
- +27.5%% change
Methodology & FAQ
How Avidity Partners Management LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Avidity Partners Management LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Avidity Partners Management LP buy in Q1 2026?
In Q1 2026, Avidity Partners Management LP initiated 25 new positions (AKTIS ONCOLOGY INC (AKTS), VIR BIOTECHNOLOGY INC (VIR), DEXCOM INC (DXCM), HUMANA INC (HUM), TEMPUS AI INC (TEM), TENAX THERAPEUTICS INC (TENX), SATELLOS BIOSCIENCE INC (MSLE), GILEAD SCIENCES INC (GILD), STRUCTURE THERAPEUTICS INC (GPCR), CORVUS PHARMACEUTICALS I (CRVS), INSULET CORP (PODD), CHARLES RIV LABS INTL INC (CRL), HIMS & HERS HEALTH INC (HIMS), PELOTON INTERACTIVE INC (PTON), INTELLIA THERAPEUTICS INC (NTLA), ODDITY TECH LTD (ODD), ANTERIS TECHNOLOGIES GLOBAL (AVR), ABBOTT LABORATORIES (ABT), MOONLAKE IMMUNOTHERAPEUTICS (MLTX), BRIDGEBIO PHARMA INC (BBIO), ARBUTUS BIOPHARMA CORP (ABUS), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT), LEGEND BIOTECH CORP (LEGN), SAVARA INC (SVRA), TREVI THERAPEUTICS INC (TRVI)); bought more shares of PALVELLA THERAPEUTICS INC NE (PVLA), KARYOPHARM THERAPEUTICS INC (KPTI), ENLIVEN THERAPEUTICS INC (ELVN), PERSPECTIVE THERAPEUTICS (CATX), REPLIGEN CORP (RGEN) — the largest 5 of 9 adds.
What stocks did Avidity Partners Management LP sell in Q1 2026?
In Q1 2026, Avidity Partners Management LP fully sold 18 positions (CG ONCOLOGY INC (CGON), ALNYLAM PHARMACEUTICALS, INC. (ALNY), MCKESSON CORP (MCK), AGILENT TECHNOLOGIES INC (A), PFIZER (PFE), CENTENE CORP DEL (CNC), KENVUE INC (KVUE), DANAHER (DHR), THERMO FISHER SCIENTIFIC INC (TMO), NOVO-NORDISK A S (NVO), THE CIGNA GROUP (CI), CENCORA INC (COR), INSMED INC (INSM), WATERS CORP (WAT), ACADIA HEALTHCARE COMPANY IN (ACHC), INTEGER HLDGS CORP (ITGR), HEALTHEQUITY INC (HQY), IQVIA HLDGS INC (IQV) (IQV)); reduced holdings in ACADIA PHARMACEUTICALS INC. (ACAD), IMMUNIC INC (IMUX), TEVA PHARMACEUTICAL INDS LTD (TEVA), ICON PLC (ICLR) (ICLR), BOSTON SCIENTIFIC CORP (BSX) — the largest 5 of 9 reductions.
Which positions did Avidity Partners Management LP initiate in Q1 2026?
Avidity Partners Management LP established 25 new positions in Q1 2026: AKTIS ONCOLOGY INC (AKTS, 2.0%), VIR BIOTECHNOLOGY INC (VIR, 1.4%), DEXCOM INC (DXCM, 1.3%), HUMANA INC (HUM, 1.3%), TEMPUS AI INC (TEM, 0.8%), TENAX THERAPEUTICS INC (TENX, 0.8%), SATELLOS BIOSCIENCE INC (MSLE, 0.7%), GILEAD SCIENCES INC (GILD, 0.6%), STRUCTURE THERAPEUTICS INC (GPCR, 0.5%), CORVUS PHARMACEUTICALS I (CRVS, 0.4%), INSULET CORP (PODD, 0.4%), CHARLES RIV LABS INTL INC (CRL, 0.4%), HIMS & HERS HEALTH INC (HIMS, 0.3%), PELOTON INTERACTIVE INC (PTON, 0.2%), INTELLIA THERAPEUTICS INC (NTLA, 0.2%), ODDITY TECH LTD (ODD, 0.2%), ANTERIS TECHNOLOGIES GLOBAL (AVR, 0.2%), ABBOTT LABORATORIES (ABT, 0.2%), MOONLAKE IMMUNOTHERAPEUTICS (MLTX, 0.2%), BRIDGEBIO PHARMA INC (BBIO, 0.2%), ARBUTUS BIOPHARMA CORP (ABUS, 0.1%), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT, 0.1%), LEGEND BIOTECH CORP (LEGN, 0.1%), SAVARA INC (SVRA, 0.1%), TREVI THERAPEUTICS INC (TRVI, 0.0%).
Which existing positions saw the largest allocation increases for Avidity Partners Management LP in Q1 2026?
Of 9 existing positions with share-count increases in Q1 2026, the largest were: PALVELLA THERAPEUTICS INC NE (PVLA, +1.5% weight, +262.7% shares), KARYOPHARM THERAPEUTICS INC (KPTI, +0.6% weight, +244.6% shares), ENLIVEN THERAPEUTICS INC (ELVN, +3.1% weight, +185.1% shares), PERSPECTIVE THERAPEUTICS (CATX, +2.8% weight, +88.4% shares), REPLIGEN CORP (RGEN, +-0.3% weight, +54.7% shares), CORCEPT THERAPEUTICS INC (CORT, +0.1% weight, +36.4% shares), ENCOMPASS HEALTH CORP (EHC, +-0.0% weight, +32.9% shares), PHATHOM PHARMACEUTICALS INC (PHAT, +-0.4% weight, +21.0% shares), ORUKA THERAPEUTICS INC (ORKA, +6.0% weight, +15.1% shares).
Which positions did Avidity Partners Management LP fully exit in Q1 2026?
Avidity Partners Management LP fully exited 18 positions in Q1 2026: CG ONCOLOGY INC (CGON, last-reported weight 17.6%), ALNYLAM PHARMACEUTICALS, INC. (ALNY, last-reported weight 2.4%), MCKESSON CORP (MCK, last-reported weight 2.3%), AGILENT TECHNOLOGIES INC (A, last-reported weight 1.6%), PFIZER (PFE, last-reported weight 1.5%), CENTENE CORP DEL (CNC, last-reported weight 1.4%), KENVUE INC (KVUE, last-reported weight 1.2%), DANAHER (DHR, last-reported weight 1.1%), THERMO FISHER SCIENTIFIC INC (TMO, last-reported weight 1.1%), NOVO-NORDISK A S (NVO, last-reported weight 1.0%), THE CIGNA GROUP (CI, last-reported weight 0.9%), CENCORA INC (COR, last-reported weight 0.9%), INSMED INC (INSM, last-reported weight 0.9%), WATERS CORP (WAT, last-reported weight 0.9%), ACADIA HEALTHCARE COMPANY IN (ACHC, last-reported weight 0.7%), INTEGER HLDGS CORP (ITGR, last-reported weight 0.7%), HEALTHEQUITY INC (HQY, last-reported weight 0.4%), IQVIA HLDGS INC (IQV) (IQV, last-reported weight 0.3%).
Which existing positions saw the largest allocation reductions for Avidity Partners Management LP in Q1 2026?
Of 9 existing positions with share-count reductions in Q1 2026, the largest were: ACADIA PHARMACEUTICALS INC. (ACAD, -0.8% weight, -87.9% shares), IMMUNIC INC (IMUX, 0.7% weight, -85.7% shares), TEVA PHARMACEUTICAL INDS LTD (TEVA, -2.2% weight, -52.1% shares), ICON PLC (ICLR) (ICLR, -1.3% weight, -51.7% shares), BOSTON SCIENTIFIC CORP (BSX, -2.4% weight, -47.6% shares), GENMAB A/S (GMAB, -0.5% weight, -45.7% shares), NATERA (NTRA, -0.4% weight, -23.7% shares), CONTEXT THERAPEUTICS INC (CNTX, 0.3% weight, -9.2% shares), MEDTRONIC PLC (MDT, -1.1% weight, -7.1% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.